Suppliers / Cambrex Charles City

Cambrex Charles City

United States Updated 9 July 2026

Cambrex Charles City is an API manufacturer based in United States. It holds 27 active US drug master files and 8 valid CEPs across a filed portfolio of 26 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as VAI.

27
active US DMFs
8
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 7 March 2025 VAI US FDA
  • 2 May 2022 VAI US FDA
  • 22 December 2016 VAI US FDA
  • 27 February 2014 NAI US FDA
  • 2 August 2013 NAI US FDA
  • 28 February 2012 NAI US FDA
  • 26 March 2010 NAI US FDA
  • 8 October 2008 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Charles City, United States Not on file
Charles City, United States 1000119390

What they file, and where

Molecule Regulators Docs
Fentanyl EDQM, US FDA 4
Amphetamine US FDA 3
Gamma-Hydroxybutyric Acid US FDA 3
Nicotine Resinate EDQM, SFDA (Saudi Arabia) 3
Sulfasalazine EDQM, US FDA 3
Dextroamphetamine US FDA 2
Nicotine US FDA 2
Ondansetron EDQM, US FDA 2
Torasemide EDQM, US FDA 2
Aripiprazole US FDA 1
Show all 26 molecules on file
Berotralstat Dihydrochloride SFDA (Saudi Arabia) 1
Buprenorphine US FDA 1
Dexamfetamine Sulfate EDQM 1
Diclofenac US FDA 1
Erlotinib US FDA 1
Hydrocodone US FDA 1
Lapatinib US FDA 1
Lisdexamfetamine Dimesylate SFDA (Saudi Arabia) 1
Mesalazine US FDA 1
Methylphenidate US FDA 1
Ofloxacin US FDA 1
Opium US FDA 1
Remdesivir SFDA (Saudi Arabia) 1
Sodium Oxybate US FDA 1
Sofosbuvir SFDA (Saudi Arabia) 1
Voxelotor SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Show 7 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Cambrex Charles City

Does Cambrex Charles City hold a US DMF or a CEP?
Cambrex Charles City holds 27 active US drug master files and 8 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Cambrex Charles City FDA-registered?
One site operated by Cambrex Charles City carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Cambrex Charles City's last inspection go?
The most recent inspection on record closed on 7 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 8 inspections are on file.
Where does Cambrex Charles City manufacture?
2 registered sites are on record, in United States (Charles City among others). Every site is listed on this page with the register it came from.
What does Cambrex Charles City make?
26 molecules are on record against Cambrex Charles City, including Fentanyl, Amphetamine, Gamma-Hydroxybutyric Acid and Nicotine Resinate. Each links through to that molecule's full manufacturer list.
Which regulators recognise Cambrex Charles City's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Cambrex Charles City comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 10 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 7 March 2025.

Comparable suppliers

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates